
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Biology, Immunology, Cytokines |
Medical College of Pennsylvania and Hahnemann University, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania 19102-1192 [M. E. S., F. U. G., K. F., M. W.], and NIH-National Cancer Institute, Frederick, Maryland 21702 [J. R.]
Transfection of primary human prostate tumor cells (i.e., HPCA-10a, 10b, 10c, and 10d lines) with the transforming growth factor (TGF)-ß1 gene stimulated anchorage-independent growth and promoted tumor growth, angiogenesis, and metastasis after orthotopic implantation in severe combined immunodeficiency mice. In contrast, interleukin (IL)-10 transfected cells or cells cotransfected with these two genes exhibited reduced growth rates and significantly reduced angiogenesis and metastasis after 8, 12, and 16 weeks. Enzyme-linked immunosandwich assays confirmed that the respective tumors expressed elevated levels of TGF-ß1 and IL-10 in vivo. ELISAs further showed that TGF-ß1 expression induced matrix metalloproteinases-2 (MMP-2) expression, whereas IL-10 down-regulated MMP-2 expression while up regulating TIMP-1 in the transfected cells. Also, tumor factor VIII levels correlated with TGF-ß1 and MMP-2 expression and inversely with IL-10 and TIMP-1 levels. More importantly, mouse survival was zero after 46 months in mice bearing TGF-ß1- and MMP-2-expressing tumors and increased significantly in mice implanted with IL-10- and TIMP-1-expressing tumors (i.e., to >80% survival). Analysis of the metastatic lesions showed that they expressed TGF-ß1 and MMP-2 but barely detectable levels of IL-10 or TIMP-1, suggesting that IL-10 and TIMP-1 might normally block tumor growth, angiogenesis, and metastasis.
This article has been cited by other articles:
![]() |
F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Panopoulou, C. Murphy, H. Rasmussen, E. Bagli, E. K. Rofstad, and T. Fotsis Activin A Suppresses Neuroblastoma Xenograft Tumor Growth via Antimitotic and Antiangiogenic Mechanisms Cancer Res., March 1, 2005; 65(5): 1877 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lu, J.-C. Soria, X. Tang, X.-C. Xu, L. Wang, L. Mao, R. Lotan, B. Kemp, B. N. Bekele, L. Feng, et al. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers J. Clin. Oncol., November 15, 2004; 22(22): 4575 - 4583. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lai, G. Z. Rassidakis, L. J. Medeiros, L. Ramdas, A. H. Goy, C. Cutler, Y. Fujio, K. Kunisada, H. M. Amin, and F. Gilles Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Am. J. Pathol., June 1, 2004; 164(6): 2251 - 2258. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Asadullah, W. Sterry, and H. D. Volk Interleukin-10 Therapy--Review of a New Approach Pharmacol. Rev., June 1, 2003; 55(2): 241 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Soria, C. Moon, B. L. Kemp, D. D. Liu, L. Feng, X. Tang, Y.-S. Chang, L. Mao, and F. R. Khuri Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1785 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suzuki, H. Nakazato, H. Matsui, M. Hasumi, Y. Shibata, K. Ito, Y. Fukabori, K. Kurokawa, and H. Yamanaka NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer J. Leukoc. Biol., April 1, 2001; 69(4): 531 - 537. [Abstract] [Full Text] |
||||
![]() |
J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Silvestre, Z. Mallat, M. Duriez, R. Tamarat, M. F. Bureau, D. Scherman, N. Duverger, D. Branellec, A. Tedgui, and B. I. Levy Antiangiogenic Effect of Interleukin-10 in Ischemia-Induced Angiogenesis in Mice Hindlimb Circ. Res., September 15, 2000; 87(6): 448 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-J. Park, J.-I. Park, D.-S. Byun, J.-H. Park, and S.-G. Chi Mitogenic Conversion of Transforming Growth Factor-{beta}1 Effect by Oncogenic Ha-Ras-induced Activation of the Mitogen-activated Protein Kinase Signaling Pathway in Human Prostate Cancer Cancer Res., June 1, 2000; 60(11): 3031 - 3038. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Silvestre, Z. Mallat, R. Tamarat, M. Duriez, A. Tedgui, and B. I. Levy Regulation of Matrix Metalloproteinase Activity in Ischemic Tissue by Interleukin-10: Role in Ischemia-Induced Angiogenesis Circ. Res., August 3, 2001; 89(3): 259 - 264. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |